Lys53

Site Information
ENADNNtkANVTkPk SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 3934956

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 )
Disease tissue studied:	leukemia ( 10 ) , chronic myelogenous leukemia ( 10 ) , lung cancer ( 4 ) , non-small cell lung adenocarcinoma ( 4 ) , multiple myeloma ( 8 , 9 )
Relevant cell line - cell type - tissue:	A549 (pulmonary) ( 4 ) , HeLa (cervical) ( 12 ) , HEp-2 (squamous) ( 1 ) , JJN3 (plasma cell) ( 8 , 19 , 20 , 21 , 23 ) , Jurkat (T lymphocyte) ( 1 , 5 , 6 ) , K562 (erythroid) ( 10 ) , MKN-45 (gastric) ( 31 ) , NCI-H929 (B lymphocyte) ( 9 , 14 ) , NT2 (testicular) ( 11 ) , PC3 (prostate cell) ( 25 , 26 , 27 , 28 , 29 , 30 ) , RPMI-8266 (plasma cell) ( 15 , 16 , 17 , 18 ) , U266 (plasma cell) ( 24 )

Upstream Regulation
Treatments:	vorinostat ( 4 )

References
1	Akimov V, et al. (2018) UbiSite approach for comprehensive mapping of lysine and N-terminal ubiquitination sites. Nat Struct Mol Biol 25, 631-640 29967540 Curated Info
2	Lumpkin RJ, et al. (2017) Site-specific identification and quantitation of endogenous SUMO modifications under native conditions. Nat Commun 8, 1171 29079793 Curated Info
3	Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610 27184836 Curated Info
4	Wu Q, et al. (2015) Suberoylanilide hydroxamic acid treatment reveals crosstalks among proteome, ubiquitylome and acetylome in non-small cell lung cancer A549 cell line. Sci Rep 5, 9520 25825284 Curated Info
5	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
6	Udeshi ND, et al. (2013) Refined preparation and use of anti-diglycine remnant (K-ε-GG) antibody enables routine quantification of 10,000s of ubiquitination sites in single proteomics experiments. Mol Cell Proteomics 12, 825-31 23266961 Curated Info
7	Kim W, et al. (2011) Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell 44, 325-40 21906983 Curated Info
8	Beausoleil S (2010) CST Curation Set: 9660; Year: 2010; Biosample/Treatment: cell line, JJN3/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
9	Guo A (2010) CST Curation Set: 9190; Year: 2010; Biosample/Treatment: cell line, H929/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
10	Guo A (2010) CST Curation Set: 9185; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
11	Zhou J (2010) CST Curation Set: 9132; Year: 2010; Biosample/Treatment: cell line, NTERA-2/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
12	Moritz A (2010) CST Curation Set: 9062; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
13	Guo A (2009) CST Curation Set: 8679; Year: 2009; Biosample/Treatment: cell line, Karpas-620/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
14	Guo A (2009) CST Curation Set: 8673; Year: 2009; Biosample/Treatment: cell line, NCI-H929/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
15	Guo A (2009) CST Curation Set: 8668; Year: 2009; Biosample/Treatment: cell line, RPMI-8266/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
16	Guo A (2009) CST Curation Set: 8669; Year: 2009; Biosample/Treatment: cell line, RPMI-8266/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
17	Guo A (2009) CST Curation Set: 8667; Year: 2009; Biosample/Treatment: cell line, RPMI-8266/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
18	Guo A (2009) CST Curation Set: 8670; Year: 2009; Biosample/Treatment: cell line, RPMI-8266/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
19	Guo A (2009) CST Curation Set: 8650; Year: 2009; Biosample/Treatment: cell line, JJN3/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
20	Guo A (2009) CST Curation Set: 8649; Year: 2009; Biosample/Treatment: cell line, JJN3/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
21	Guo A (2009) CST Curation Set: 8651; Year: 2009; Biosample/Treatment: cell line, JJN3/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
22	Guo A (2009) CST Curation Set: 8653; Year: 2009; Biosample/Treatment: cell line, KMS-12-BM/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
23	Guo A (2009) CST Curation Set: 8652; Year: 2009; Biosample/Treatment: cell line, JJN3/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
24	Guo A (2009) CST Curation Set: 8644; Year: 2009; Biosample/Treatment: cell line, U266/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
25	Possemato A (2009) CST Curation Set: 8587; Year: 2010; Biosample/Treatment: cell line, PC3/Velcade; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
26	Possemato A (2009) CST Curation Set: 8585; Year: 2010; Biosample/Treatment: cell line, PC3/Geldanamycin; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
27	Possemato A (2009) CST Curation Set: 8583; Year: 2010; Biosample/Treatment: cell line, PC3/AAG; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
28	Possemato A (2009) CST Curation Set: 8581; Year: 2010; Biosample/Treatment: cell line, PC3/control; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
29	Possemato A (2009) CST Curation Set: 8582; Year: 2010; Biosample/Treatment: cell line, PC3/AAG; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
30	Possemato A (2009) CST Curation Set: 8584; Year: 2010; Biosample/Treatment: cell line, PC3/Geldanamycin; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
31	Guo A (2008) CST Curation Set: 5566; Year: 2008; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info